Drug Profile
Peripheral white blood cell therapeutics - Aposcience
Alternative Names: APO-1; APO-2; Apoptotic-PBMCs; APOSEC™Latest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Aposcience
- Developer Aposcience; Medical University of Vienna
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Diabetic foot ulcer
- Preclinical Myocardial infarction; Wounds
Most Recent Events
- 06 Dec 2023 Aposcience completes phase I/II trials in Diabetic Foot ulcers in Austria, Germany, Poland, Czech Republic (NCT04277598) (EudraCT2018-001653-27)
- 31 Aug 2023 Preclinical development for Diabetic foot ulcer and myocardial infarction (MI) is ongoing Austria (Aposcience AG website, August 2023)
- 09 Oct 2020 Phase-I/II clinical trials in Diabetic foot ulcer in Germany, Poland (Topical) (NCT04277598)